---
document_datetime: 2026-02-10 11:14:12
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/carvykti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: carvykti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 17.9956398
conversion_datetime: 2026-02-13 18:20:11.634126
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.2
  docling: 2.73.1
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## CARVYKTI

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA / | A.5Changeinthenameand/oraddressofa | 10/02/2026                          |                                          | Annex II                        |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| EMA/VR/0000323641                     | manufacturer/importer of the finished product (including batch release or quality control testing sites)-A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |                |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------|
| Variation type II / EMA/VR/0000290398 | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a startingmaterial/reagent/intermediateused in themanufacturingprocessof the active substance orchangein themanufacturer (including whererelevant quality control testingsites)oftheactivesubstance,where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relatesto abiologicalactive substance or a starting material/reagent/intermediate used inthemanufactureofa biological/immunologicalproduct-Accepted B.I.a.1 Change in the manufacturer of a startingmaterial/reagent/intermediateused in themanufacturingprocessof theactive substanceorchangeinthemanufacturer (includingwhererelevantqualitycontrol testingsites)of the activesubstance,where no Ph. Eur. Certificate of Suitability is part of the approved dossier-B.I.a.1.jChanges to quality control testing arrangements for a | 29/01/2026 | Not applicable |

<div style=\"page-break-after: always\"></div>

|                                        | addition of a site where batch control/testing includingabiological /immunological / immunochemicalmethodtakesplace- Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |      |                                                                                                                                                                                                                                |
|----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000312774  | This was an application for a group of variations. B.I.d.1 Change in the re-test period/storage period or storage conditions of the active substance wherenoPh.Eur.Certificate of Suitability covering theretestperiodispart of the approved dossier - B.I.d.1.b Change instorageconditionsof thereference standard. The same principles will apply as outlinedfor the active substance.-Accepted B.I.d.1 Change in the re-test period/storage period or storage conditions of the active substance where noPh.Eur.Certificate of Suitability covering the retest period is part of the approved dossier - B.I.d.1.b Change in storage conditions of the reference standard.The same principleswill apply as outlined forthe active substance.-Accepted | 17/11/2025 |      |                                                                                                                                                                                                                                |
| Variation typeIA_IN/ EMA/VR/0000294863 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.z Change(s)in the Summary of product Characteristics, LabellingorPackageLeafletintendedto implementtheoutcomeofaPRACsignal recommendation:implementationofwording agreed by the competent authority that do                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 04/09/2025 | SmPC | Toupdatesection4.4of theSmPCtoimplement the signal recommendations on'Ciltacabtagene autoleucel;idecabtagenevicleucel;tisagenlecleucel -Progressivemultifocal leukoencephalopathy (EPITT no20153)'adoptedatthe10July2025 PRAC. |

<div style=\"page-break-after: always\"></div>

|                                       | notrequire anyfurther assessment- Accepted                                                                                                                                                                                                                                                                                                                                     |            |    |                  |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----|------------------|
| Article 61(3) /                       | - Notification acc. Article 61(3) - Accepted Updateofthepackageleafletwiththe additionof thecountryofdestination in section'7. Expiry date and other batch specific information' in the 'Particulars To Appear On The Lot Information Sheet IncludedWithEachShipmentForOne Patient'.                                                                                           | 07/02/2025 | PL | EMA/N/0000244636 |
| Variation type IB / EMA/VR/0000287523 | B.II.b.2 Change to importer,batch release arrangements and quality control testing of thefinishedproduct-B.II.b.2.a Replacementoradditionofasitewhere batch control/testing takes place - Accepted                                                                                                                                                                             | 20/08/2025 |    |                  |
| Variation type IB / EMA/VR/0000303915 | Thiswas an applicationfor agroupof variations. B.1.b.2Change in test procedurefor active substance or starting material/reagent/intermediateused in the manufacturing process of the active substance -B.I.b.2.a Minor changes to an approved test procedure -Accepted B.I.b.2 Changein test procedure for active substance or starting material/reagent/intermediateusedinthe | 07/11/2025 |    |                  |

<div style=\"page-break-after: always\"></div>

|                                          | manufacturingprocessofthe active substance-B.I.b.2.a Minor changes to an approved test procedure -Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |             |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation type IA_IN / EMA/VR/0000285927 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling orPackageLeaflet intended to implementtheoutcomeofaPRACsignal recommendation: implementation of wording agreed by the competent authority that do notrequire anyfurther assessment- Accepted                                                                                                                                                                                                                                                                         | 11/07/2025 | SmPC and PL |
| Variation type II / EMA/VR/0000258113    | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in themanufacturingprocessof the active substance orchange in themanufacturer (including where relevant quality control testingsites)oftheactivesubstance,where noPh.Eur.Certificate ofSuitabilityispart of the approved dossier - B.I.a.1.k New storage siteofMasterCellBankand/orWorkingCell Banks-Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active | 24/07/2025 |             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                       | (includingwhererelevantquality control testing sites)of the active substance,where noPh.Eur.Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a startingmaterial/reagent/intermediateused inthemanufactureofa biological/immunologicalproduct-Accepted                                                                                                                                                                                                                              |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000264446 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.4 Change(s) in the Summary of Product Characteristics, LabellingorPackageLeafletduetonew quality, preclinical, clinical or pharmacovigilance data - Accepted Updateofsection4.4oftheSmPCinorder to amend an existing warning on Secondary malignanciesincluding of T-cell origintolimit the testing only to secondary malignancy of T-cell originbased on the datafromclinical studies and literature and to giveinstruction onmonitoringandtestingofsecondary malignancy of any type in treated patients with HIV. | 24/07/2025 | SmPC | SmPCnewtext:Patientsshouldbemonitored life- longforsecondarymalignancies.Intheevent a secondary malignancy occurs, the company should be contacted for reporting and to obtain instructions on patient samples to collect for testing of secondarymalignancy of T-cell origin.Inpatients withHIVinfection,contact the companyforthe testing of secondary malignancies, including those ofnon-Tcell origin.Formoreinformation,please refertotheSummaryofProductCharacteristics. |
| PSUR/EMA/PSUR/0000274460              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |      | Maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PASS/EMA/PASS/0000264227              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 05/06/2025 |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000302993   | B.I.b.2 Changein test procedure for active substance or starting material/reagent/intermediateused inthe manufacturingprocessoftheactive substance-B.I.b.2.aMinorchangestoan approved test procedure-Accepted                                                                                                                             | 27/10/2025   |                            |                                                                                                                                                |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| PASS/EMA/PASS/0000256848                |                                                                                                                                                                                                                                                                                                                                           | 08/05/2025   |                            |                                                                                                                                                |
| Variation typeIA/ EMA/VR/0000278722     | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Deletionofonemanufacturingprocessofthe active substance manufacturingprocesses- Accepted                                                                                                                                                                 | 11/06/2025   |                            |                                                                                                                                                |
| VariationtypeIB/ EMA/VR/0000280863      | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in themanufacturingprocess of the activesubstance-Accepted                                                                                                                                                                                  | 18/07/2025   |                            |                                                                                                                                                |
| Variation typeII / EMA/VR/0000272240    | This was an application for a group of variations. A.ADMINISTRATIVECHANGES-A.7 Deletion ofmanufacturingsitesforan active substance,intermediate orfinished product, packaging site, manufacturer responsible for batchrelease,sitewherebatch control takes place，orsupplierofastartingmaterial, reagent orexcipient(when mentioned in the | 18/09/2025   | Annex II, Labelling and PL | TheAnnexII hasbeenupdated asfollows:Toadd themanufactureroftheactivesubstanceandbatch releasesite.Thepackageleaflethasbeenupdated accordingly. |

<div style=\"page-break-after: always\"></div>

| dossier)*- Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunologicalproductandanyof thetestmethodsperformed atthesiteis a biological/immunological method-Accepted B.II.b.2 Change to importer,batch release arrangements and quality control testing of the finished product -B.1I.b.2.b Replacementoradditionofasitewhere batchcontrol/testingtakesplacefor a biological/immunologicalproductandanyof thetestmethodsperformed atthesiteis a biological/immunological method - Accepted B.II.b.2 Change to importer,batch release arrangements and quality control testing of the finished product -B.11.b.2.b Replacementoradditionofasitewhere batchcontrol/testingtakesplacefor a biological/immunologicalproduct andanyof thetest methodsperformed atthesite is a biological/immunological method-Accepted B.II.b.2 Change to importer,batch release arrangements and quality control testing of the finished product -B.11.b.2.b Replacementoradditionofasitewhere batchcontrol/testingtakesplacefor a biological/immunological product and any of thetestmethodsperformedatthesiteis a   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                       | biological/immunological method-Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product -B.1I.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.2.cReplacement or addition of a manufacturerresponsibleforimportation and/or batch release - B.11.b.2.c.3 Including batchcontrol/testingfora biological/immunological product andany of thetestmethodsperformed atthatsiteisa biological / immunological / immunochemical method- Accepted B.II.b.1Replacement or addition of a manufacturingsiteforpartor allofthe manufacturing process of the finished product - B.11.b.1.c Site where any manufacturing operation(s) take place, exceptbatchrelease，batchcontrol,and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes- Accepted   |            |                |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------|
| Variation type II / EMA/VR/0000281226 | B.1.b.2Changein testprocedurefor active substance orstarting material/reagent/intermediateusedinthe manufacturing process of the active substance - B.1.b.2.d Substantial change to orreplacementofabiological/                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 18/09/2025 | Not applicable |

<div style=\"page-break-after: always\"></div>

|                                       | immunological/immunochemicaltest methodoramethodusingabiological reagent for a biological active substance - Accepted                                                                                                                                                                                                                                        |            |                |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------|
| Variation type II / EMA/VR/0000302440 | B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.f Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product - Accepted                                                                                                                       | 11/12/2025 | Not applicable |
| Variation type II / EMA/VR/0000285085 | B.I.b.1 Change in the specification parameters and/or limits of an active substance,startingmaterial/intermediate/ reagent used in the manufacturing process of the active substance-B.I.b.1.e Deletion of a specification parameter which may have a significant effect on the overall quality of the activesubstance and/or thefinished product - Accepted | 18/09/2025 | Not applicable |
| Variation type II / EMA/VR/0000264849 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturingprocessofthe active substance -B.I.b.2.d Substantial change to orreplacementofabiological/ immunological/immunochemicaltest                                                                                                         | 19/06/2025 |                |

<div style=\"page-break-after: always\"></div>

| method or a method using a biological reagent for a biological active substance - Accepted   |
|----------------------------------------------------------------------------------------------|